May 10, 2018 / 11:12 AM / 10 days ago

BRIEF-Oncolytics Biotech Receives Special Protocol Assessment Agreement From FDA For Phase 3 Clinical Trial Of Pelareorep In Metastatic Breast Cancer

May 10 (Reuters) - Oncolytics Biotech Inc:

* ONCOLYTICS BIOTECH® RECEIVES SPECIAL PROTOCOL ASSESSMENT AGREEMENT FROM FDA FOR PHASE 3 CLINICAL TRIAL OF PELAREOREP IN METASTATIC BREAST CANCER Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below